▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #691 by analyst upside · 2026-09-27
PTHS
Pelthos Therapeutics Inc.
Healthcare · Market Cap $85M · P/E 0x
ANALYST PRICE TARGET
+139.5%
implied upside to consensus target
Current Price $22.19
Consensus Target $53.14
Bull Target $64.0
Bear Target $45.0
Analysts Covering 7
ANALYST CONSENSUS - BUY
Strong Buy
1
Buy
6
Hold
0
Sell
0
52-Week Low $18.19
52-Week High $37.5
YTD Return -24.7%
FUNDAMENTALS
Market Cap $85M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-28.63
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $43M
Profit Margin -199.5%
52-WEEK RANGE
52-Week Low $18.19
52-Week High $37.5
Current Price $22.19
Bear Target $45.0
Bull Target $64.0
● Now $22.19 ● Target $53.14
TRADING DATA
Avg Volume 61K
YTD Return -24.7%
Analyst Count 7
Consensus Buy
Upside to Target +139.5%
Last Updated 2026-09-27

ANALYST SUMMARY

Pelthos Therapeutics Inc. (PTHS) is currently trading at $22.19 with a Wall Street consensus price target of $53.14, implying potential upside of 139.5% over the next 12 months. 7 analysts currently cover PTHS, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $64.0, while the most cautious has a target of $45.0.

PTHS operates in the Healthcare sector with a market capitalisation of $85M. The stock is down 24.7% year-to-date and is currently trading near the lower end of its 52-week range of $18.19 – $37.5.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for PTHS, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Oppenheimer - Reiterated
Outperform → Outperform 2026-08-14 14% win rate (7 calls)
Oppenheimer - Reiterated
Outperform → Outperform 2026-05-15 14% win rate (7 calls)
Cantor Fitzgerald ● Initiated
Overweight 2026-04-01 40% win rate (10 calls)
Oppenheimer - Reiterated
Outperform → Outperform 2026-03-20 14% win rate (7 calls)
HC Wainwright & Co. reit
Buy → Buy 2026-03-19 31% win rate (48 calls)
Piper Sandler ● Initiated
Overweight 2026-02-27 14% win rate (7 calls)
Roth Capital - Reiterated
Buy → Buy 2026-02-26 Building track record
Oppenheimer - Reiterated
Outperform → Outperform 2026-01-26 14% win rate (7 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
56
out of 100
Coverage depth
16/30
Consensus clarity
13/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →